Viridian Therapeutics, Inc.\DE (VRDN) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
VRDN currently has 102M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 51.29% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 05, 2026 |
10-Q filing | 102.2M shares outstanding |
100M | 0 |
| Nov 05, 2025 |
10-Q filing | 95.4M shares outstanding |
95M | 0 |
| Aug 06, 2025 |
10-Q filing | 81.6M shares outstanding |
82M | 0 |
| May 06, 2025 |
10-Q filing | 81.3M shares outstanding |
81M | 0 |
| Mar 03, 2025 |
10-K filing | 81.5M shares outstanding |
81M | 0 |
| Nov 12, 2024 |
10-Q filing | 79.2M shares outstanding |
79M | 0 |
| Aug 08, 2024 |
10-Q filing | 63.9M shares outstanding |
64M | 0 |
| May 08, 2024 |
10-Q filing | 61.1M shares outstanding |
61M | 0 |
| Feb 27, 2024 |
10-K filing | 62.8M shares outstanding |
63M | 0 |
| Nov 13, 2023 |
10-Q filing | 52.6M shares outstanding |
53M | 0 |
| Aug 08, 2023 |
10-Q filing | 43.3M shares outstanding |
43M | 7.8M |
| May 10, 2023 |
10-Q filing | 42.2M shares outstanding |
42M | 8.8M |
| Mar 09, 2023 |
10-K filing | 42.9M shares outstanding |
43M | 8.2M |
| Nov 14, 2022 |
10-Q filing | 40.2M shares outstanding |
40M | 11M |
| Aug 15, 2022 |
10-Q filing | 27.8M shares outstanding |
28M | 23M |
| May 13, 2022 |
10-Q filing | 26.1M shares outstanding |
26M | 25M |
| Mar 11, 2022 |
10-K filing | 25.9M shares outstanding |
26M | 25M |
| Nov 08, 2021 |
S-3 filing: The company is filing an S-3 to offer common stock, preferred stock, debt securities, warrants and/or units, at prices and on terms that we will determine at the time of the offering. |
19M | 32M |
| Nov 05, 2021 |
10-Q filing | 21.7M shares outstanding |
22M | 7M |
| Aug 12, 2021 |
10-Q filing | 9.6M shares outstanding |
9.6M | 19M |
| May 07, 2021 |
10-Q filing | 8.4M shares outstanding |
8.4M | 20M |
| Mar 26, 2021 |
10-K filing | 7.2M shares outstanding |
7.2M | 21M |
| Dec 17, 2020 |
8-K filing: Miragen Therapeutics, Inc. issued 322,407 shares of its common stock to Xencor, Inc. in a private placement as upfront payment for a technology license agreement. |
3 | 29M |
| Dec 15, 2020 |
S-3 filing: This S-3 filing discusses prior private placements of common stock and warrants in February 2020 and Series A Preferred Stock in October 2020, as well as potential future equity issuances under equity incentive plans. |
3 | 29M |
| Nov 13, 2020 |
Stock Split
8-K filing: Stock split 1-for-15 | Outstanding: 58,663,753 → 3 |
3 | 28M |
| Nov 12, 2020 |
10-Q filing | 58.7M shares outstanding |
59M | 360M |
| Aug 05, 2020 |
10-Q filing | 56.6M shares outstanding |
57M | 360M |
| May 08, 2020 |
10-Q filing | 53.1M shares outstanding |
53M | 360M |
| Mar 26, 2020 |
S-3 filing: The filing is for a delayed offering under SEC Rule 415 registering an indeterminate number of shares of common stock and preferred stock, such indeterminate principal amount of debt securities, and such indeterminate number of warrants to purchase common stock, preferred stock, and/or debt securities, as may be sold by the Registrant from time to time, which together shall have an aggregate initial offering price not to exceed $175,000,000. |
53M | 360M |
| Mar 13, 2020 |
10-K filing | 53.1M shares outstanding |
53M | 0 |